Advanced thymic cancer treated with carboplatin and paclitaxel in a patient undergoing hemodialysis

Intern Med. 2015;54(1):55-8. doi: 10.2169/internalmedicine.54.3484. Epub 2015 Jan 1.


A 53-year-old man with an asymptomatic anterior mediastinal tumor undergoing hemodialysis was referred to our institution. He was diagnosed with thymic basaloid carcinoma based on the findings of a chest tomography-guided biopsy and successfully treated with carboplatin (300 mg/m(2)/day) and paclitaxel (200 mg/m(2)/day) on day 1 for six three-week cycles. To our knowledge, this is the first report regarding the efficiency of a carboplatin dose-definition method based on the body surface area with paclitaxel in a hemodialysis patient. This report may therefore be useful for treating hemodialysis patients who are candidates for carboplatin and paclitaxel therapy.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carboplatin / administration & dosage*
  • Humans
  • Male
  • Middle Aged
  • Paclitaxel / administration & dosage*
  • Renal Dialysis*
  • Thymoma / drug therapy*
  • Thymus Neoplasms / drug therapy*
  • Treatment Outcome


  • Carboplatin
  • Paclitaxel